Third Animal Implantation Completed - Trials Continue

Press Release 27 October, 2022

Realheart announces it has performed a third implantation in sheep to test the clinical version of Realheart TAH – the version that will also be used in clinical trials expected to start in 2024. 3-4 more implantations are now planned in the series.

The surgery was performed in an animal laboratory in Belgium by the same surgical team as in previous trials: Dr Dilek Gürsoy and Dr Joeri van Puyvelde, led by Professor Bart Meyns. Once again, the implantation went quickly and progress was made, including the optimal placement of the pump.

''I am very pleased to confirm that the series continues and that more implantations are now scheduled and I look forward to reporting the results once all the analyses are complete'' says Ina Laura Perkins, CEO of Realheart.

This disclosure contains information that Real Heart is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information in this press release has been published through the agency of the contact persons set out below, at the time stated by Scandinavian Real Heart AB’s news distributor Cision upon publication of this press release.

For more information please contact:

Ina Laura Perkins, CEO

Phone: +46(0)70 406 49 21 

E-mail: inalaura.perkins@realheart.se

Certified Adviser: Svensk Kapitalmarknadsgranskning AB, Phone: +46 11 32 30 732, email: ca@skmg.se

Scandinavian Real Heart AB develops a total artificial heart (TAH) for implantation in patients with life-threatening heart failure. Realheart® TAH has a patented design that resembles that of the natural human heart. The artificial heart consists of a four-chamber system (two atria and two ventricles) designed to generate a physiological blood flow pattern that mimics the body's natural circulation. A unique concept in the medical technology world.